A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides

Clinical and Experimental Dermatology

Volumn 29, Issue 3, 2004, Pages 231-236

  Child, F J ^a,c   Mitchell, T J ^a   Whittaker, S J ^a   Scarisbrick, J J ^a   Seed, P T ^b   Russell Jones, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EXTRACORPOREAL PHOTOPHERESIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; PHOTOPHERESIS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 2442652880     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01525.x     Document Type: Article

References (22)

1. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93.
2. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
3. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.
4. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988; 91: 120-4.
5. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-5.
6. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987; 316: 297-303.
7. Heald P, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-33.
8. Fraser-Andrews E, Seed P, Whittaker S, Russell-Jones R, Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998; 134: 1001-5.
9. Blaydon J, Taylor P. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease. Br J Haematol 1999; 107: 707-11.
10. Rook A, Suchia K, Kao D et al. Photopheresis: clinical applications and mechanism of action. J Invest Dermatol (Symp Proc) 1999; 4: 85-90.
11. Russell-Jones R. Shedding light on photopheresis. Lancet 2001; 357: 820-1.
12. Berger C, Longley B, Imaeda S et al. Tumour specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor. Int J Cancer 1998; 76: 304-11.
13. Fraser-Andrews EA, Woolford AJ, Russell-Jones R et al. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000; 114: 117-21.
14. Hönigsmann H, Brenner W, Rauschmeier W et al. Photochemotherapy for cutaneous T cell lymphoma: a follow-up study. J Am Acad Dermatol 1984; 10: 238-45.
15. Abel EA, Sendagorta E, Hoppe RT, Hu C-H. PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten year follow-up study. Arch Dermatol 1987; 123: 897-901.
16. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-9.
17. Wollina U, Looks A, Meyer J et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001; 44: 253-60.
18. Zic JA, Sticklin GP, Greer JP et al. Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-45.
19. Armus S, Keyes B, Cahill C et al. Photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1990; 23: 898-902.
20. Rubegni P, de Aloe G, Fimiani M. Extracorporeal photochemotherapy in long-term treatment of early stage cutaneous T-cell lymphoma. Br J Dermatol 2000; 143: 894-5.
21. Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-57.
22. Evans AV, Wood BP, Scarisbrick JJ et al. Extracorporeal photopheresis in Sezary syndrome: Haematological parameters as predictors of response. Blood 2001; 98: 1298-301.